Hippocampal‐amygdalo‐ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models
Human Brain Mapping. 2022-04-07; :
DOI: 10.1002/hbm.25850
Lire sur PubMed
Coupé P(1), Manjón JV(2), Mansencal B(1), Tourdias T(3)(4), Catheline G(5), Planche V(6).
Author information:
(1)CNRS, Univ. Bordeaux, Bordeaux INP, Talence, France.
(2)ITACA, Universitat Politècnica de València, Valencia, Spain.
(3)Inserm U1215 – Neurocentre Magendie, Bordeaux, France.
(4)Service de neuroimagerie, CHU de Bordeaux, Bordeaux, France.
(5)INCIA, EPHE, Université PSL, Univ Bordeaux, CNRS, Bordeaux, France.
(6)Univ. Bordeaux, CNRS, UMR 5293, Institut des Maladies Neurodégénératives, and Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
In this article, we present an innovative MRI-based method for Alzheimer disease
(AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan
trajectories of brain structures. After a full screening of the most discriminant
structures between AD and normal aging based on MRI volumetric analysis of 3,032
subjects, we propose a novel Hippocampal-Amygdalo-Ventricular Atrophy score
(HAVAs) based on normative lifespan models and AD lifespan models. During a
validation on three external datasets on 1,039 subjects, our approach showed very
accurate detection (AUC ≥ 94%) of patients with AD compared to control subjects
and accurate discrimination (AUC = 78%) between progressive MCI and stable MCI
(during a 3-year follow-up). Compared to normative modeling, classical machine
learning methods and recent state-of-the-art deep learning methods, our method
demonstrated better classification performance. Moreover, HAVAs simplicity makes
it fully understandable and thus well-suited for clinical practice or future
pharmaceutical trials.
© 2022 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.